IntelGenx Enters Into Amended and Restated License Agreement with Tetra Bio-Pharma for Adversa® Mucoadhesive Delivery Techno...
October 21 2020 - 6:00AM
IntelGenx Corp. (TSX-V:IGX)(OTCQB:IGXT) (the "Company" or
"IntelGenx") today announced that it has entered into an amended
and restated license agreement (the “Agreement”) granting Tetra
Bio-Pharma (TSX:TBP)(OTCQB:TBPMF)(“Tetra”), a leader in
cannabinoid-derived drug discovery and development, additional
exclusive worldwide rights, including the right to manufacture,
IntelGenx’s Adversa
® mucoadhesive delivery
technology.
The Adversa® technology is
designed to limit first-pass metabolism, improve bioavailability,
enhance product stability and reduce gastro-intestinal exposure and
side-effects. Tetra will use the Adversa® technology to develop a
THC-based mucoadhesive film containing its PPP-002 (Dronabinol)
drug candidate for the treatment of chemotherapy-induced nausea and
vomiting.
Under the terms of the Agreement, Tetra is
purchasing the worldwide Adversa® technology rights as it relates
to its PPP-002 (Dronabinol) drug product candidate for three
undisclosed milestone payments: 45% to be paid on November 15,
2020; 45% to be paid on March 1, 2021, and a final payment of 10%
upon successful technology transfer. In addition, Tetra will pay
IntelGenx a low single digit royalty on future net sales of
Dronabinol mucoadhesive tablets.
“This agreement reflects the many potential
therapeutic benefits of our Adversa® delivery technology,” said
Dr. Horst G. Zerbe, CEO of IntelGenx. “In addition to
being particularly well-suited for patients who have difficulty
swallowing capsules – a common and unfortunate side effect of
chemotherapy – Adversa® offers comparable efficacy to capsules,
with a potentially superior side-effect profile.”
Steeve Néron, Tetra’s Chief Commercial Officer,
commented, “We are looking forward to applying the Adversa®
technology to our PPP-002 drug candidate with the goal of providing
better therapeutic value for both patients with
chemotherapy-induced nausea and vomiting and their caregivers.”
About Tetra
Bio-Pharma
Tetra Bio-Pharma is a biopharmaceutical leader
in cannabinoid-based drug discovery and development with FDA and
Health Canada approved clinical programs aimed at bringing novel
prescription drugs and treatments to patients and their healthcare
providers. Our evidence-based scientific approach has enabled us to
develop a pipeline of cannabinoid-based drug products for a range
of medical conditions, including pain, inflammation, and oncology.
With patients at the core of what we do, Tetra Bio-Pharma is
focused on providing rigorous scientific validation and safety data
required for inclusion into the existing biopharma industry by
regulators, physicians and insurance companies. For more
information visit: www.tetrabiopharma.com.
About IntelGenx
IntelGenx is a leading drug delivery company
focused on the development and manufacturing of pharmaceutical
films.
IntelGenx’s superior film technologies,
including VersaFilm® and VetaFilm™, as well as VevaDermTM, its
transdermal development and manufacturing capabilities, allow for
next generation pharmaceutical products that address unmet medical
needs. IntelGenx’s innovative product pipeline offers significant
benefits to patients and physicians for many therapeutic
conditions.
IntelGenx's highly skilled team provides
comprehensive pharmaceuticals services to pharmaceutical partners,
including R&D, analytical method development, clinical
monitoring, IP and regulatory services. IntelGenx's
state-of-the-art manufacturing facility offers full service by
providing lab-scale to pilot- and commercial-scale production. For
more information, visit www.intelgenx.com.
Forward Looking Statements:
This document may contain forward-looking
information about IntelGenx' operating results and business
prospects that involve substantial risks and uncertainties.
Statements that are not purely historical are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and Section 27A of the Securities
Act of 1933, as amended. These statements include, but are not
limited to, statements about IntelGenx' plans, objectives,
expectations, strategies, intentions or other characterizations of
future events or circumstances and are generally identified by the
words "may," "expects," "anticipates," "intends," "plans,"
"believes," "seeks," "estimates," "could," "would," and similar
expressions. All forward looking statements are expressly qualified
in their entirety by this cautionary statement. Because these
forward-looking statements are subject to a number of risks and
uncertainties, IntelGenx' actual results could differ materially
from those expressed or implied by these forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, those discussed under
the heading "Risk Factors" in IntelGenx' annual report on Form
10-K, filed with the United States Securities and Exchange
Commission and available at www.sec.gov, and also filed with
Canadian securities regulatory authorities at www.sedar.com.
IntelGenx assumes no obligation to update any such forward-looking
statements.
Each of the TSX Venture Exchange and OTCQB has
neither approved nor disapproved the contents of this press
release. Neither TSX Venture Exchange nor its Regulation Services
Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or
accuracy of this release.
Source: IntelGenx Technologies Corp.
For IntelGenx:
Stephen KilmerInvestor Relations (514) 331-7440 ext
232stephen@intelgenx.com
Or
Andre Godin, CPA, CAPresident and CFOIntelGenx Corp.(514)
331-7440 ext 203andre@intelgenx.com
Tetra Bio Pharma (TSX:TBP)
Historical Stock Chart
From Mar 2024 to Apr 2024
Tetra Bio Pharma (TSX:TBP)
Historical Stock Chart
From Apr 2023 to Apr 2024